CCCC C4 Therapeutics, Inc.

Nasdaq c4therapeutics.com


$ 2.39 $ 0.04 (1.7 %)    

Thursday, 06-Nov-2025 11:37:04 EST
QQQ $ 611.98 $ -9.81 (-1.58 %)
DIA $ 468.40 $ -3.63 (-0.77 %)
SPY $ 670.31 $ -6.14 (-0.91 %)
TLT $ 89.79 $ 0.23 (0.26 %)
GLD $ 365.86 $ -1.24 (-0.34 %)
$ 2.37
$ 2.34
$ 2.38 x 900
$ 2.39 x 870
$ 2.33 - $ 2.46
$ 1.09 - $ 6.45
1,586,117
na
229.69M
$ 2.46
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-07-2025 03-31-2025 10-Q
4 02-27-2025 01-01-1970 10-K
5 10-31-2024 09-30-2024 10-Q
6 08-01-2024 06-30-2024 10-Q
7 05-08-2024 03-31-2024 10-Q
8 02-22-2024 12-31-2023 10-K
9 11-01-2023 09-30-2023 10-Q
10 08-08-2023 06-30-2023 10-Q
11 05-04-2023 03-31-2023 10-Q
12 02-23-2023 12-31-2022 10-K
13 11-03-2022 09-30-2022 10-Q
14 08-04-2022 06-30-2022 10-Q
15 05-05-2022 03-31-2022 10-Q
16 02-24-2022 12-31-2021 10-K
17 11-10-2021 09-30-2021 10-Q
18 08-11-2021 06-30-2021 10-Q
19 05-13-2021 03-31-2021 10-Q
20 03-11-2021 12-31-2020 10-K
21 11-12-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 c4-therapeutics-q3-eps-044-misses-040-estimate-sales-11230m-beat-6280m-estimate

C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0...

 c4-therapeutics-13g-filing-shows-point72-asset-management-lp-reports-99-passive-stake-in-co-as-of-oct-17-2025

- SEC Filing

 wells-fargo-maintains-overweight-on-c4-therapeutics-raises-price-target-to-10

Wells Fargo analyst Derek Archila maintains C4 Therapeutics (NASDAQ:CCCC) with a Overweight and raises the price target from...

 stephens--co-reiterates-overweight-on-c4-therapeutics-maintains-6-price-target

Stephens & Co. analyst Sudan Loganathan reiterates C4 Therapeutics (NASDAQ:CCCC) with a Overweight and maintains $6 pric...

 barclays-initiates-coverage-on-c4-therapeutics-with-overweight-rating-announces-price-target-of-8

Barclays analyst Etzer Darout initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Overweight rating and announces Pri...

 stephens--co-upgrades-c4-therapeutics-to-overweight-raises-price-target-to-6

Stephens & Co. analyst Sudan Loganathan upgrades C4 Therapeutics (NASDAQ:CCCC) from Equal-Weight to Overweight and raise...

 guggenheim-initiates-coverage-on-c4-therapeutics-with-buy-rating-announces-price-target-of-8

Guggenheim analyst Brad Canino initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Buy rating and announces Price Tar...

 c4-therapeutics-q2-eps-037-beats-041-estimate-sales-6463m-beat-5240m-estimate

C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.4...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION